Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...

A young specialist explores a paradigm shift in the cyclical 'treat, respond, relapse, repeat' approach to therapy for ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support ...

Trials evaluating the safety and necessity of omitting systemic mediastinal lymph node (mLN) dissection in non-small cell lung cancer (NSCLC ... found to predict the EFS or OS outcome (Figures S1A, B) ...

CHARLESTON — Health Secretary Robert F. Kennedy Jr. announced a landmark initiative to expand access to cutting-edge treatments for sickle cell disease, a genetic blood disorder that ...

The company is now pinning its hopes on CB-010, a therapy for non-Hodgkin’s lymphoma, and CB-011, for multiple myeloma. With CB-010, Caribou is enrolling patients in a Phase 1 trial in second-line ...

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin lymphoma. Until recently, patients whose disease returned after standard chemo-immunotherapy faced limited ...

is showing real promise in treating patients with diffuse large B-cell lymphoma that has either returned or not responded to other treatments. CAR T-cell therapy is a revolutionary treatment approach ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Carly Stafford Dixon, a survivor of primary mediastinal b-cell lymphoma (a rare type of blood cancer) and a patient advocate, sat down for an interview with CURE to discuss the topic of adolescents ...